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During a community echovirus type 33 outbreak, the virus was detected in the feces and cerebrospinal fluid
of a 3-year-old boy with right arm weakness that followed a mild nonspecific febrile illness. This is the first time
an association between echovirus type 33 infection and acute flaccid paralysis has been reported.
CASE REPORT
In August 2000, a previously healthy 3-year-old boy pre-
sented to the Wellington Children’s Hospital, Wellington, New
Zealand, with acute flaccid paralysis (AFP) of his right arm.
Four days earlier he had experienced a febrile illness with a
clear nasal discharge, mild vomiting, and diarrhea. On the
morning of admission he awoke complaining of a painful right
shoulder and had limited movement of this arm. He had re-
ceived all his routine childhood immunizations, including the
oral poliomyelitis vaccine at 6 weeks and 3 and 5 months of
age. There was no recent travel history, and other household
members were well.
On examination he was afebrile and irritable but nontoxic
and had no rash or meningeal signs. Except for the right arm,
the neurologic examination was unremarkable. The right arm
was hypotonic and areflexic. On the right he had 4/5 power in
his hand, 2/5 flexion and extension at the wrist, 3/5 flexion and
2/5 extension at the elbow, and 1/5 abduction and adduction of
the shoulder. There was no sensory loss or bulbar involvement.
Hematological investigations included a hemoglobin level of
11.7g/dl, a platelet count of 355  109/liter, a total leukocyte
count of 11.7  109/liter, and an erythrocyte sedimentation
rate of 8 mm/h. Magnetic resonance imaging showed no evi-
dence of cord swelling. In the sagittal T-2 weighted images, a
bilateral high signal intensity was seen posteriorly in the pons
extending down the brain stem and spinal cord to the low
thoracic level. In the axial T-2 weighted images, there was an
increased signal localized to the grey matter bilaterally, with
greater accentuation on the right side. There was no enhance-
ment with gadlinium. Lumbar puncture produced clear cere-
brospinal fluid (CSF) with 53  106 white blood cells (91%
lymphocytes) per liter, a protein concentration of 27 mg/dl,
and a glucose concentration of 50 mg/dl. No organisms were
seen on Gram staining, and bacterial pathogens were not de-
tected by culture.
At the time of the patient’s illness there was a community
outbreak of echovirus type 33 (E33) infection (8). That out-
break began in March 2000 in the Waikato region of New
Zealand’s North Island and spread 325 miles south to Well-
ington, where 17 cases were reported between June and No-
vember of that year. The outbreak lasted 9 months and was
widespread throughout the North Island. A total of 75 cases
were reported, mostly involving children with meningitis. Out-
break isolates were submitted by regional virology laboratories
to the National Polio Reference Laboratory at the Institute of
Environmental Science and Research (ESR), Porirua, Well-
ington, for further characterization. Initial typing by antibody
neutralization tests with Lim and Benyesh-Melnick (9a) pools
had suggested that these isolates were E33 strains. However,
confirmatory neutralization tests at ESR with pooled and
monospecific antisera (National Institute for Public Health
and the Environment, Bilthoven, The Netherlands) against
E33 were inconclusive. The outbreak strain’s identity as E33
was finally established by molecular serotyping. Generic re-
verse transcription (RT)-PCR primers that amplify all human
enterovirus serotypes were used to amplify a portion of the
VP1 capsid gene, the sequence of which has been shown to
correlate with the serotype (10). The partial VP1 sequence was
78.4% identical to that of the prototype E33 strain (96.8%
amino acid identity) and less than 70% identical to all other
enterovirus VP1 sequences, confirming the isolate’s identity as
E33. An E33-specific RT-PCR test was developed on the basis
of the sequences of the outbreak strains and other E33 se-
quences available at the Centers for Disease Control and Pre-
vention. Primer 158S (5-GCI AGI ARI CCI GAR GAY C-3;
E33 VP1 nucleotides 247 to 265) anneals to a site that encodes
an E33-specific amino acid motif (ASKPEDQ), whereas
primer 159A (5-CCI CCI GGN GGI ACR TAC AT-3; E33
nucleotides 434 to 452) anneals to a site that encodes a motif
that is highly conserved among all enteroviruses (MYVPPGG).
It was during this E33 outbreak, which included 17 cases
within the local community, that the patient’s pharyngeal se-
cretions, CSF, and three fecal samples collected 3, 6, and 7
days after the onset of paralysis were transported to ESR.
These specimens were inoculated into HF, RD, MEK, Hep-2,
and L20B cells (12). All cell lines except the poliovirus-specific
L20B cells inoculated with the three fecal specimens yielded
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E33 viruses, with typing confirmed by sequencing. Later, PCR
testing of these cell lines established the presence of a 206-bp
E33-specific amplicon identical to those of other E33 clinical
isolates and the E33 prototype strain (Fig. 1). E33 RNA was
also detected in the patient’s CSF by the serotype-specific
RT-PCR, but the result could not be confirmed by repeat
testing because of insufficient sample volume (data not shown).
The isolate responsible for AFP was further sequenced, and
the resulting VP1 sequence (Fig. 2) differed from that of the
prototype E33 strain by 21.6% (3.2% amino acid difference).
No other viruses or bacterial pathogens were detected in the
fecal or respiratory secretions, and serological evidence for
recent mycoplasma or Epstein-Barr virus infection was lacking.
Nonpoliovirus enterovirus complement fixation titers of 1:16
were detected in serum collected on the day of admission. No
convalescent-phase serum was available for testing.
Meanwhile, the boy initially received methylprednisolone,
which was followed by a marked reduction in his irritability.
Sixty days later movement had returned to his hand, wrist, and
elbow, but shoulder abduction was limited to 30° and deltoid
muscle wasting was present. After 1 month his tendon reflexes
had returned but his muscle wasting persisted, especially wast-
ing of the right shoulder muscle. At that stage he had almost
normal power in his hand, wrist, and elbow but was unable to
abduct his arm beyond 60°. Two years later his parents re-
ported further improvement in arm movement and power,
although shoulder muscle wasting remains.
The E33 prototype strain, Toluca-3, was isolated from a
child in Toluca, Mexico, in 1959 (11). Since then, E33 has been
linked to outbreaks and sporadic cases of meningitis, respira-
tory disease, gastroenteritis, and abortion in several Northern
Hemisphere countries (2, 4, 13). However, to our knowledge
this is the first time that E33 has been associated with paralytic
disease.
Several features of this boy’s illness suggest E33 as the pos-
sible causative agent. The virus was isolated from several fecal
specimens, and serotype-specific PCR testing of the CSF de-
tected the 206-bp E33-specific amplicon. The finding of a non-
specific low titer of enterovirus antibodies in an acute-phase
serum sample implies that the fecal shedding of E33 most
likely followed recent exposure. Moreover, his presentation
FIG. 1. Specific amplification of E33 outbreak isolates by RT-PCR
with the 158S-159A primer set. Lanes 1 to 12, clinical E33 isolates
involved in an outbreak; lane N, negative control; lane M, molecular
size marker.
FIG. 2. Pairwise comparison of VP1 nucleotide sequences showing sequence differences between the E33 fecal isolate from the patient with
AFP (NEZ00-812) and the E33 prototype strain, Toluca-3. The locations of diagnostic primers 158S and 159A are also indicated.










occurred in the setting of an E33 outbreak in which several
cases were concurrently identified in the local community.
None of the patients with these other E33 cases developed
AFP, although among those older than 12 months of age,
nearly 90% had aseptic meningitis (8). Finally, no other patho-
gens were detected and no other causes of AFP were identified
(5, 9). Unfortunately, convalescent-phase serum was not avail-
able to demonstrate type-specific seroconversion.
World Health Organization reports of nonpoliovirus entero-
viruses from 1967 to 1970 found that paralysis was present in
less than 1% of all patients with echovirus and coxsackievirus
type A and B infections reported (1). However, as the global
eradication of polioviruses approaches, proportionately more
cases of nonpoliovirus enterovirus infections causing AFP and
mimicking acute paralytic poliomyelitis will emerge. Of the at
least 20 nonpoliovirus enterovirus serotypes associated with
AFP, coxsackievirus types A7 and A9, the group B coxsack-
ieviruses, echovirus type 9, and enterovirus type 71 are the
most commonly encountered (5–7). Although the majority of
cases are mild and transient, persistent muscle weakness, as
illustrated by the case of the young child described here, or
even death has been reported.
As the spectrum of nonpoliovirus enteroviruses causing AFP
continues to expand (3), we report on E33 as a possible agent
associated with this illness. E33 and other enteroviruses should
be considered in the course of AFP surveillance activities in
countries where poliovirus has been eradicated.
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